Leaving no cancer behind.
The Rainbow Probe
Detects Cancerous Tissue During Surgery on the Patient's Body
r.
The Rainbow Probe Detects Cancerous Tissue During Surgery on the Patient's Body
Real-time verification that the cavity surface is free of cancerous tissue.
Precision surgical guidance.
Any cancer surgery
ends up with one critical question on the surgeon’s mind:
Did I remove all the cancer?
Surgeons currently lack real-time information to confirm complete tumor removal
leading to repeated surgeries and billions $ healthcare costs each year
NUTEK’s SOLUTION
Pioneering precision in surgical oncology, NUTEK develops an AI-powered, handheld hyperspectral imaging scanner that enables real-time detection of residual cancerous tissue during surgery.
Its technology transforms tumor removal from subjective estimation to objective, data-driven precision, reducing re-operations and improving patient outcomes.
Backed by a multidisciplinary leadership team and proven clinical validation, NUTEK is positioned to disrupt the multi-billion-dollar guided surgery market.
Cancer tissue left undetected in the patient’s body results in:
Roughly 1,000,000 cases require repeat surgery
$10 billion per year in excess cost worldwide
Increased aggressive treatment, patient post-op pain, recovery time, and risk of cancer reoccurrence
Introducing:
The Rainbow Probe
Samples live tissue directly on the patient's body, during surgery, to alert surgeons to the existence of residual cancerous tissue, and provides guidance for their further removal.
Combining analysis of very high-resolution 2D image with precise spectral tissue classification
The Rainbow scanner uses an advanced miniaturized hyperspectral imaging device and a unique optical system to provide surgeons with real-time data on the live tissue scanned.
- Patent pending
- AI cloud-based algorithms
- Real-time analysis response
Press
Achievements
Established an EU subsidiary
NUTEK AT GmbH, a fully owned subsidiary, located in Graz Austria.
Rainbow MVP
Ex-vivo Minimum Viable Product
TRL 6, developed and built
FFG Grant
Grant awarded from the Austrian government
Successful Human Breast Cancer experiment
Ex-vivo animal testing and human breast cancer experiments were completed successfully.
Further breast cancer experiments using the MVP are now underway
Space tech
Accepted to ESA Business Incubator for innovative use of space-based technology
Our partner
Nutek AT GmbH. has formed a unique collaboration with the Medical University of Graz, Austria where first human breast cancer experiment took place.
Our team
Steven Eitan, Active Chairman
A seasoned global business leader with over 35 years of experience as CEO, CFO and strategic advisor. Brings expertise in healthcare, Medical Devices and technology. Conducted businesses across North America, Europe, LATAM, Asia and Africa.
Prof. Hanoch Kashtan M.D,
Co-Founder & Medical Director
Director of Surgery at ASSUTA Medical Center, Surgical Oncologist, Chair Scientific Council of the Israel Medical Association, and Member of the European Society of Surgical Oncology (ESSO). Founder of Medical Device companies. Wide international medical network
Dov Cohen, Co-Founder & CEO
Experienced leader of teams developing multi-disciplinary national airborne programs, EW, Radar and C4ISR, Director of Space Systems, Corporate Director of Business Development at Israel Aerospace Industries. Led development of Hyper Spectral remote sensing applications
Ofer Braun, Co-Founder & CTO
Expert in the design and production of optical medical devices systems. Formerly Director of Space Hyper-spectral Imaging at Elbit Systems. Successfully led the development of unique optical and hyperspectral, space and airborne cameras and sensors.
We’d love to hear from you
Want to find out more about Nutek and the Rainbow probe? Contact us today by filling in the adjacent form.
Tel Aviv, Israel
+972 (0)52 366-3483
Contact Us
